bendamustine fresenius kabi 2,5 mg/ml inj. sol. (pwdr., conc.) i.v. vial
fresenius kabi sa-nv - bendamustine hydrochloride 25 mg - powder for concentrate for solution for infusion - 2,5 mg/ml - bendamustine hydrochloride 25 mg - bendamustine
bendamustine fresenius kabi 2,5 mg/ml inj. sol. (pwdr., conc.) i.v. vial
fresenius kabi sa-nv - bendamustine hydrochloride 25 mg - powder for concentrate for solution for infusion - 2,5 mg/ml - bendamustine hydrochloride 100 mg - bendamustine
bendared (bendamustine hydrochloride concentrate for solution for infusion 180mg4ml)
dr. reddy`s laboratories malaysia sdn. bhd. - bendamustine hydrochloride -
ribomustin 100 mg
astellas pharma international b.v., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
ribomustin 25 mg
astellas pharma international b.v., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
ribomustin 100 mg
dor pharmaceutical services ltd., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
ribomustin 25 mg
dor pharmaceutical services ltd., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
bendamustine hydrochloride seacross 25mgvial powder for concentrate for solution for infusion
medispec (m) sdn.bhd - bendamustine hydrochloride monohydrate -
bendamustine hydrochloride seacross 100mgvial powder for concentrate for solution for infusion
medispec (m) sdn.bhd - bendamustine hydrochloride monohydrate -
bendamustine hydrochloride intravenous infusion 100mg/4ml "towa" (ベンダムスチン塩酸塩点滴静注液100mg/4ml「トーワ」)
towa pharmaceutical co., ltd. - bendamustine hydrochloride hydrate - injection